Study on the Vibration and Sound Radiation Performance of Micro-Perforated Laminated Cylindrical Shells

In response to the problem of vibration and noise reduction in equipment with cylindrical shell structures, this paper focuses on the micro-perforated laminated cylindrical shell structure and establishes its finite element model. Through comparative analysis with experimental results, the reliability of the finite element modeling method is verified. Based on this, the paper places particular emphasis on the vibration and acoustic radiation performance of the structure in the 1–1000 Hz frequency range under free conditions to understand the impact of different laminated shell structures, micro-perforation parameters (porosity, aperture), sound-absorbing foam materials, and placement methods. The results indicate that micro-perforated structures can efficiently reduce the structural radiated sound power level at specific frequencies, but the overall reduction in radiated sound power level is not significant. Various types of foam are effective in reducing the structural radiation acoustic power level, with polyurethane performing best among them. Changing the location of foam placement has a relatively insignificant impact on the structural radiation acoustic power level.© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).fi=vertaisarvioitu|en=peerReviewed

Effects of mulberry twig alkaloids(Sangzhi alkaloids) and metformin on blood glucose fluctuations in combination with premixed insulin-treated patients with type 2 diabetes

IntroductionWe aimed to evaluated the effect of premixed insulin (Ins), premixed insulin combined with metformin (Ins+Met) or mulberry twig alkaloids(Ins+SZ-A) on blood glucose fluctuations in patients with type 2 diabetes (T2DM) using continuous glucose monitors (CGM).MethodsThirty patients with T2DM and poor blood glucose control using drugs were evaluated for eligibility during the screening period. Subsequently, their original hypoglycemic drugs were discontinued during the lead-in period, and after receiving Ins intensive treatment for 2 weeks, they were randomly assigned to receive either Ins, Ins+Met, or Ins+SZ-A treatment for the following 12 weeks. The main efficacy endpoint comprised changes in their CGM indicators changes (mean blood glucose level [MBG], standard deviation of blood glucose [SDBG], mean amplitude of glycemic excursions [MAGE], postprandial glucose excursions [PPGE], the largest amplitude of glycemic excursions [LAGE], mean of daily difference [MODD], time in range between 3.9–10.0 mmol/L [TIR] and area under the curve for each meal [AUCpp]) during the screening, lead-in, and after 12-week treatment period. Changes in glycosylated hemoglobin (HbA1c), fasting blood glucose (FBG), 1-h postprandial blood glucose (1h-PBG), 2-h postprandial blood glucose (2h-PBG), fasting blood lipids and postprandial blood lipids were also measured at baseline and after 12 weeks of treatmentResultsThe CGM indicators of the three groups during the lead-in period all showed significant improvements compared to the screening period (P<0.05). Compared with those in the lead-in period, all of the CGM indicators improved in the the Ins+Met and Ins+SZ-A groups after 12 weeks of treatment (P<0.05), except for MODD. After 12-week treatment, compared with the Ins group, Ins+Met and Ins+SZ-A groups showed improved MBG, SDBG, TIR, breakfast AUCpp,lunch AUCpp, HbA1c, FBG, 1h-PBG, fasting blood lipid and postprandial blood lipid indicators (P<0.05). Further, the LAGE, PPGE, MAGE, dinner AUCpp and 2h-PBG levels of the Ins+SZ-A group were significantly lower than those of the Ins+Met and Ins groups (P<0.05).ConclusionOur findings highlight the efficacy of combination therapy (Ins+SZ-A or Ins+Met) in improving blood glucose fluctuations, as well as blood glucose and lipid levels. Ins+SZ-A reduces postprandial blood glucose fluctuations more than Ins+Met and Ins groups.Trial registration numberISRCTN20835488

The anti-tumor activity of tangeretin in esophageal squamous cell carcinoma by inhibiting GLI2-mediated transcription of GPNMB.

Tangeretin (Tan), a citrus flavonoid, possesses a strong anti-tumor efficacy in various human cancers. However, the precise role of Tan in the development of esophageal squamous cell carcinoma (ESCC) remains unclear. RNA sequencing (RNA-seq) analysis was performed to observe the Tan-related genes in Tan-treated TE-1 cells. The direct relationship between GLI family zinc finger 2 (GLI2) and the promoter of glycoprotein non-metastatic melanoma protein B (GPNMB) was predicted by bioinformatics analysis and validated by luciferase reporter and chromatin immunoprecipitation (ChIP) assays. Cell survival after Tan treatment was assessed by CCK8 assay. Gene expression levels were evaluated by a qRT-PCR, western blot, or immunofluorescence method. Cell migration and invasion were detected by wound-healing and transwell assays. The function of Tan in vivo was examined using xenograft studies. Our data indicated anti-migration and anti-invasion functions of Tan in ESCC cells in vitro. Tan also diminished tumor growth in vivo. Mechanistically, Tan diminished the expression and transcriptional activity of GLI2 in ESCC cells. Silencing of GLI2 resulted in decreased expression of GPNMB by inhibiting GPNMB transcription via the binding site at the GPNMB promoter at position +(1539-1550). Moreover, Tan down-regulated GPNMB expression in ESCC cells, and re-expression of GPNMB reversed anti-migration and anti-invasion functions of Tan in ESCC cells. Our findings uncover anti-migration and anti-invasion effects of Tan in ESCC cells by down-regulating GPNMB by suppressing GLI2-mediated GPNMB transcription, providing new evidence that Tan can function as a therapeutic agent against ESCC

MCIR-YOLO: White Medication Pill Classification Using Multi-Band Infrared Images

The identification and categorization of pills constitute critical tasks within a contemporary hospital, particularly for avoiding medication errors. Conventional approaches to visual recognition and classification predominantly rely on visible light imagery, proving inadequate for discerning white pills with similar visual characteristics. However, white pills exhibit distinctive infrared properties across various spectral bands. Building upon these observations, this paper introduces the MCIR-YOLO algorithm, a multi-band infrared image object detection system, which enhances the YOLOv5s model through multimodal fusion techniques. This study presents a novel dataset comprising IR images of white round pills captured across six channels, with peak wavelengths ranging from approximately 1400 nm to 1650 nm. Furthermore, a multimodal fusion strategy is proposed, facilitating multi-level feature integration across the six IR channels. This fusion technique exploits the scale features inherent to each IR modality, thereby enabling comprehensive information fusion across multiple modalities. Additionally, the model incorporates an auxiliary detection branch, independent of the backbone, which utilizes fused feature information to calculate a distinct loss, effectively mitigating overall loss. Attention mechanism modules are integrated after two distinct fusion points to enhance feature precision. Leveraging mean and scaling of IR features, these attention mechanisms significantly boost detection accuracy. Experimental results demonstrate that the improved model outperforms the baseline YOLOv5s model, particularly evident in a self-constructed dataset of white round pill IR images, where mAP0.5 increased by 5.47% and 7.96% for single-channel (peak at 1650 nm) and six-channel configurations, respectively. Notably, the utilization of the MCIR-YOLO model for six-channel recognition yields a substantial advantage of 12.05% over the best-performing single-channel IR image recognition